The STA Management
Regional biopharmaceutical company focused on in-licensing, regulatory approval, market access and commercialisation of specialist therapies across Australia, New Zealand and Southeast Asia. Activities include regulatory and reimbursement submissions, pre-launch planning, commercial operations, expanded access/compassionate use programs, clinical stakeholder engagement, and supply chain management including temperature-controlled distribution. The company also provides philanthropic support and partners with international biotech and pharmaceutical companies to bring mid-to-late stage compounds to these markets.
Industries
Nr. of Employees
small (1-50)
The STA Management
Headquartered in Singapore; representative offices in Melbourne (Australia) and Auckland (New Zealand)
Products
Nanoparticle albumin-bound chemotherapy formulation (regional commercialisation)
Regional introduction and commercial management of a solvent-free, nanoparticle albumin-bound paclitaxel chemotherapy formulation, including achievement of national reimbursement listings for oncology indications.
Fluorescence-guided tumour visualisation agent (regional licensing)
Regional licensing and commercialisation of an aminolevulinic acid-based fluorescence-guided tumour visualisation agent to support intraoperative neurosurgical tumour identification.
Genomic recurrence score diagnostic (regional distribution)
Partnership to distribute a genomic diagnostic assay for breast cancer recurrence risk and prognostic stratification to clinicians in the region.
Targeted small-molecule tyrosine kinase inhibitor (regional licence)
Regional licensing and commercial activities for a targeted tyrosine kinase inhibitor used in specific haematology and oncology indications.
Nanoparticle albumin-bound chemotherapy formulation (regional commercialisation)
Regional introduction and commercial management of a solvent-free, nanoparticle albumin-bound paclitaxel chemotherapy formulation, including achievement of national reimbursement listings for oncology indications.
Fluorescence-guided tumour visualisation agent (regional licensing)
Regional licensing and commercialisation of an aminolevulinic acid-based fluorescence-guided tumour visualisation agent to support intraoperative neurosurgical tumour identification.
Genomic recurrence score diagnostic (regional distribution)
Partnership to distribute a genomic diagnostic assay for breast cancer recurrence risk and prognostic stratification to clinicians in the region.
Targeted small-molecule tyrosine kinase inhibitor (regional licence)
Regional licensing and commercial activities for a targeted tyrosine kinase inhibitor used in specific haematology and oncology indications.
Services
Preparation and management of regulatory and payer submissions across Australia, New Zealand and Southeast Asia.
In-licensing, local commercial strategy, launch planning and ongoing product commercial management for regionally licensed therapies.
Market preparation including payer communications, KOL cultivation and investigator engagement prior to product launch.
Administration of compassionate access programs and special access initiatives to provide therapies before or alongside reimbursement.
Regional distribution and logistics for specialty medicines, including cold-chain handling and temperature monitoring.
Field medical engagement and scientific education activities with emphasis on clinician-focused scientific exchange rather than sales volume incentives.
Preparation and management of regulatory and payer submissions across Australia, New Zealand and Southeast Asia.
In-licensing, local commercial strategy, launch planning and ongoing product commercial management for regionally licensed therapies.
Market preparation including payer communications, KOL cultivation and investigator engagement prior to product launch.
Administration of compassionate access programs and special access initiatives to provide therapies before or alongside reimbursement.
Regional distribution and logistics for specialty medicines, including cold-chain handling and temperature monitoring.
Field medical engagement and scientific education activities with emphasis on clinician-focused scientific exchange rather than sales volume incentives.
Expertise Areas
- Regulatory submissions and reimbursement strategy for ANZ and Southeast Asia
- Regional commercialisation and in-licensing
- Market access and payer engagement
- Clinical stakeholder engagement and investigator networks
Key Technologies
- Genomic diagnostic assays
- Nanoparticle-based chemotherapy formulations
- Fluorescence-guided tumour visualisation agents
- Cold-chain logistics and temperature monitoring
News & Updates
Announcement of an expanded distribution and commercial partnership to add additional therapies to the regional portfolio.
Announcement of regulatory approval for a paediatric endocrinology therapy in Australia.
Summary of a phase III metastatic melanoma study showing a statistically significant improvement in progression-free survival versus standard chemotherapy.
Notification that a nanoparticle albumin-bound paclitaxel formulation was granted orphan drug status by the national regulator for pancreatic cancer.
Report of phase III MPACT trial results showing improved overall survival and secondary endpoints for the combination regimen compared to gemcitabine alone.
Reported therapies used to treat approximately 160,000 patients regionally.
Announcement of an expanded distribution and commercial partnership to add additional therapies to the regional portfolio.
Announcement of regulatory approval for a paediatric endocrinology therapy in Australia.
Summary of a phase III metastatic melanoma study showing a statistically significant improvement in progression-free survival versus standard chemotherapy.
Notification that a nanoparticle albumin-bound paclitaxel formulation was granted orphan drug status by the national regulator for pancreatic cancer.
Report of phase III MPACT trial results showing improved overall survival and secondary endpoints for the combination regimen compared to gemcitabine alone.
Reported therapies used to treat approximately 160,000 patients regionally.